Skip to content
The Joe Rogan ExperienceThe Joe Rogan Experience

Joe Rogan Experience #1854 - Rick Strassman

Rick Strassman is a Clinical Associate Professor of Psychiatry at the University of New Mexico School of Medicine. He is the author of numerous scientific papers and books, among them "DMT: The Spirit Molecule." His most recent, "The Psychedelic Handbook: A Practical Guide to Psilocybin, LSD, Ketamine, MDMA, and Ayahuasca," is available now. www.rickstrassman.com

Joe RoganhostRick Strassmanguest
Jun 27, 20243h 30mWatch on YouTube ↗

CHAPTERS

  1. 0:00 – 1:36

    Reconnecting with Strassman and why his DMT study mattered

    Joe and Rick catch up on when they first connected and why Strassman’s work stood out. They frame his DMT research as one of the first major U.S. human psychedelic studies after decades of shutdown.

    • First contact in mid-2000s and early Rogan-era interest in Strassman’s book
    • Context: long pause in U.S. human psychedelic research
    • Strassman’s work positioned as a rare FDA-approved Schedule I research effort
    • Setting the agenda: motivations, permissions, and scientific legitimacy
  2. 1:36 – 7:21

    First altered-state experiences: hash, chemistry curiosity, and early risk awareness

    Strassman describes an intensely psychedelic first cannabis/hash experience that sparked his lifelong interest in brain chemistry. The conversation quickly expands to potency differences and how powerful experiences can destabilize some users.

    • Shared hallucination-like experience from strong hash as a teenager
    • How potency (hash vs. marijuana) changes likelihood of intense effects
    • Strassman’s early chemistry background and curiosity about brain mechanisms
    • Early recognition that altered states can be profound and unpredictable
  3. 7:21 – 13:41

    Psychedelics, vulnerability, and psychosis: when minds ‘fracture’

    Joe and Rick discuss how psychedelics can precipitate mental-health crises in vulnerable people. They compare drug-triggered episodes to paranoid schizophrenia patterns and emphasize genetics, life stressors, and trauma as risk multipliers.

    • Examples of psychedelic overuse leading to paranoia, mania, and hospitalization
    • Genetic predisposition + life instability as key risk factors
    • Psychological ‘trauma’ of a massive trip (good or bad) can destabilize identity
    • Paranoid delusions evolve with culture (radio waves → brain chips)
  4. 13:41 – 15:48

    ‘Portals’ and prolonged breaks: the McKenna mushroom story as a model

    The discussion shifts to reports of unusually long-lasting disruptions after heavy psychedelic use. Strassman offers a ‘portal’ framing: the drug may open an altered state that doesn’t close quickly, even after the compound leaves the body.

    • Question: how can effects persist weeks after psilocybin exposure?
    • Strassman’s “portal stayed open” hypothesis as a psychological/spiritual model
    • Joe’s tension between metaphor (“portal”) and mechanism (“neurochemistry”)
    • Implication: altered states can reset perception and reality-testing
  5. 15:48 – 20:55

    DMT as another dimension vs. brain phenomenon—and how you’d test it

    Joe presses on whether the DMT realm is internal hallucination or an external ‘place.’ Strassman suggests experiments would be needed, but admits the measurement problem is enormous, leading them to discuss VR as a partial analogue for transcendence.

    • Debate: ‘another place’ vs. ‘chaos in the brain’ framing
    • Speculative experimental approaches (physics/parallel realities/imaging)
    • Virtual reality research claiming transcendence-like effects
    • Artist reconstructions (e.g., DMT-like art) as clues but not proof
  6. 20:55 – 24:43

    Endogenous DMT and the pineal gland: what newer studies suggest

    They review newer findings about DMT produced in mammals and how levels may change around death, particularly in visual brain regions. The pineal gland theory is treated as controversial, while the bigger idea becomes a possible DMT neurotransmitter system.

    • 2019-era research: endogenous DMT increases during death; visual cortex focus
    • Pineal DMT: mixed evidence and disputes about earlier findings
    • Possibility of a DMT ‘neurotransmitter system’ comparable to serotonin
    • Practical difficulty of measuring DMT in blood; brain/spinal fluid more relevant
  7. 24:43 – 49:34

    From pineal mystique to prions: why humans mythologize organs (and risk them)

    A tangent connects pineal ‘third eye’ reverence with darker historical practices and biology. They discuss cannibalism myths, prion disease (CJD), and why organ-eating traditions exist despite severe risks.

    • Why ancient cultures revered the pineal (unpaired organ, subjective sensations)
    • Aztec sacrificial/ritual stories tied to hormones/‘power’ beliefs
    • Prion diseases (CJD, mad cow) and organ/brain consumption risks
    • Family anecdotes (Italian lamb brains) and cultural food practices
  8. 49:34 – 1:06:15

    Strassman’s long path to approval: melatonin research as a backdoor into psychedelics

    Strassman outlines a decades-long strategy: medical training, psychiatric research skills, and pineal/melatonin studies as a legitimate foundation. The goal was to build credibility and infrastructure before attempting DMT research.

    • Early ambition: combine Freud, Buddhism, and psychopharmacology—rejected in interviews
    • Medical school, psychiatry, and Alaska work connected to circadian biology
    • UNM melatonin/pineal study built clinical research credentials
    • Strategic pivot: melatonin wasn’t psychedelic, but it opened the institutional door
  9. 1:06:15 – 1:12:04

    Funding DMT in the ‘War on Drugs’: permits, NIDA, and the Masons coincidence

    They detail how Strassman secured support by framing DMT research through public-health and psychosis angles, rather than spirituality. Funding sources included NIDA and an unexpected early grant from a Masonic schizophrenia foundation, which leads to a discussion of optics and legitimacy.

    • Advice from supervisors: “Get grants, publish, stay out of the newspaper”
    • Government openness once rigorous safety protocols were in place
    • NIDA/NIH as key funder; grant framing emphasized risk/psychosis relevance
    • Scottish Rite (Masons) schizophrenia research grant—mundane explanation via mentor
  10. 1:12:04 – 1:18:10

    Religious exemptions and Oregon’s psilocybin rollout: governance vs. chaos

    Joe asks how ayahuasca churches (UDV, Santo Daime) won legal protections and what that implies for U.S. policy. They compare court-driven exemptions with Oregon’s attempt to regulate psilocybin centers, and discuss practical pitfalls (banking, safety, local bans).

    • UDV/Santo Daime origins in Brazil and U.S. legal battles over importation
    • Pragmatic strategies: seek permits vs. get caught and litigate
    • Oregon model: certified centers/sitters and county-level pushback
    • Implementation problems mirrored from early cannabis legalization (cash, crime, banking)
  11. 1:18:10 – 1:30:03

    5-MeO-DMT, ‘white-out’ states, and the risks of chasing the afterglow

    They contrast NN-DMT’s information-rich experiences with 5-MeO-DMT’s ego-dissolving ‘white-out’ and discuss why some people use 5-MeO habitually. Joe and Rick share destabilizing after-effects (‘slippery’ reality) and emphasize integration, moderation, and mental-health support.

    • 5-MeO-DMT: ‘going away,’ white-out, cleansing afterglow, and addiction risk
    • Joe’s lingering two-week instability after repeated DMT sessions
    • Strassman’s unsettling 5-MeO experience and value of therapy/integration
    • Harm reduction: stop excessive use; treat lingering distress like trauma/PTSD
  12. 1:30:03 – 2:07:48

    Protocol design and early IV dosing: why IV, what went wrong, and what they learned

    Strassman explains the scientific logic behind dosing protocols and why the team used IV DMT rather than smoking or IM injections. He recounts early over-dosing incidents that produced terror and amnesia, and how the study refined to a ‘stiff’ but manageable high-dose standard.

    • Dose-response methodology: small/medium/large and full effect characterization
    • Why IV over smoking: dosing precision, fewer confounds, faster delivery, less lung exposure
    • Early mistake: dosing too high led to overwhelm, fear, vomiting, poor recall
    • Study design choices: psychedelic-experienced volunteers for safety and better reports
  13. 2:07:48 – 3:30:07

    Shared experiences, telepathy research, and the future: set/setting, centers, and control

    The conversation broadens to group phenomena (shared hallucinations, ESP/telepathy claims) and what future technology might do to consciousness and privacy. They close on practical ethics: how to build safe environments, avoid ‘party DMT’ disasters, and create structures (centers/churches) that maximize benefit while reducing harm.

    • Parapsychology angle: David Luke’s studies and claims of enhanced telepathy
    • Set and setting as decisive variables; cautionary ‘pizza party DMT’ story
    • Debate over legalization models: education-first vs. prescription/government control
    • Ayahuasca church structure (UDV): frequent ceremonies, moral framework, and positive outcomes reported

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.